Charity set up in memory of Brighton teenager features on BBC Breakfast
A charity set up in memory of a Brighton teenager has been featured on BBC Breakfast.
Founded in memory of Charlotte Eades, Charlotte's BAG was featured on BBC Breakfast in a seven-minute segment, highlighting the legacy of the young woman.
At 16, Charlotte was diagnosed with glioblastoma multiforme, a rare and fast-growing brain cancer.
She documented her journey with honest and heartfelt YouTube videos, reaching nearly 25 million viewers worldwide.
By sharing her story, she aimed to help others live life to the fullest, despite the uncertain future a cancer diagnosis brings.
Her mother, Alex Eades, founded Charlotte's BAG, which has raised more than £325,000 to support research at King's College Hospital.
The research focuses on quick whole genome sequencing of brain tumours to improve diagnosis and treatment.
The charity is entirely self-funded, meaning all public donations go directly to research.
The charity operates with no salaries, advertising, or merchandise, run solely by a family inspired by Charlotte's story.
Even costs such as PayPal fees and the PO Box are paid privately, ensuring every penny donated has an impact.
Charlotte's BAG is striving to change the fact that brain tumour research receives only one per cent of the annual cancer research funding, and treatments have seen little progress since the 1990s.
Thanks to Charlotte's BAG's contributions, research is now carrying out detailed molecular analysis within 24 hours of surgery.
Mr Ranj Bhangoo, a consultant neurosurgeon said in the BBC interview: "By getting as much genetic and molecular information as possible, we can make a decision with the patient about how their tumour is going to behave.
"We are routinely now able to offer this analysis to patients."
The charity continues to honour Charlotte's spirit of courage, humour, and generosity, fuelling breakthroughs in care and giving hope to young people facing brain cancer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Report forecasts tech-driven vision for NHS could add £40bn to annual UK GDP
With profound change in sight for the UK's National Health Service (NHS), a new report indicates that a technology-driven vision for the national health system could add £40bn ($54.8bn) to the nation's annual GDP. Co-authored by Boston Consulting Group (BCG), Siemens Healthineers, and Imperial College London, the report follows the UK Spending Review on 11 June, in which Chancellor of the Exchequer Rachel Reeves announced that the NHS will receive a £29bn ($39.1bn) funding boost, reflecting a 3% annual rise on current levels over the next three years to reach £226bn by 2029. Reeves also revealed that the funding would increase the NHS's technology budget by almost 50%, with £10bn ($13.5bn) of the total funding earmarked to bring the 'analogue health system into the digital age'. Commissioned by the NHS as input to its 10-Year Plan, which is anticipated to be released in early July, the report foresees that innovation in diagnosis has the potential to impact population outcomes through risk stratification and intervention to 'prevent disease and alleviate burden on the broader healthcare system'. According to the research, by addressing health inequalities through predictive, personalised and preventative care, two to three million healthy life years could be added to the five most economically deprived groups among the UK population each year, thereby boosting the UK's GDP by around £40bn each year. Achieving this aim would primarily be driven by implementing technologies such as AI for the early diagnosis of diseases such as cancer, the report stated. Also, the report envisions the deployment of AI and technologies including remote patient monitoring tools, to take preventative action on conditions such as high blood pressure and hypertension that are well-established predicates of life-threatening conditions such as coronary artery disease (CAD), stroke, and cancer. In turn, the report forecasts that the impact of technologies' deployment in the NHS would deliver £12bn-£18bn ($16.4-$24.7bn) in productivity gains for NHS healthcare systems annually. By integrating diagnostic data into NHS R&D, the report also forecasts that drug development timelines could be reduced, resulting in new drugs being brought to patients up to twice as fast, with operational cost savings and commercial data revenue worth £10bn-£15bn ($13.7bn- $20.5bn) to the NHS annually. Ben Horner, managing director and partner at BCG and co-author of the report, said: 'As the UK Government prepares to set out its 10-Year Health Plan, this research highlights the scale of the opportunity ahead. 'By embracing technology and data-driven innovation, the NHS could add over £40bn to UK GDP annually. This would improve patient outcomes, easing pressure on frontline services and boosting productivity across the system. The foundations are already in place; now is the moment to shift from pilots to full-scale implementation.' "Report forecasts tech-driven vision for NHS could add £40bn to annual UK GDP" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
